Entrectinib

Chemical formula: C₃₁H₃₄F₂N₆O₂ Molecular mass: 560.65 g/mol PubChem compound: 25141092

Therapeutic indications

Entrectinib is indicated for:

Solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion

Population group: only minors (0 - 18 years old) , adults (18 years old or older)

Entrectinib as monotherapy is indicated for the treatment of adult and paediatric patients older than 1 month with solid tumours that have a NTRK gene fusion,

who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
who have not received a prior NTRK inhibitor
who have no satisfactory treatment options.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

For patients >1 month to ≤6 months of age 250 mg/m² BSA once daily and for patients >6 months of age 250 mg/m² BSA or 100-600 mg once daily based on BSA

ROS1-positive, advanced non-small cell lung cancer

Population group: only adults (18 years old or older)

Entrectinib as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Entrectinib is contraindicated in the following cases:

Lactation

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.